Home » Topics » BioWorld Science

BioWorld Science
RSS

Phase II trial investigates TIMP-GLIA in subjects with celiac disease

Feb. 5, 2019

Aprea initiates phase III study of APR-246 and azacitidine for TP53 mutant MDS

Feb. 5, 2019

I-Mab and BCT to collaborate on arginine depletion therapy

Feb. 5, 2019

Biohaven plans to advance BHV-3500 into phase II for acute treatment of migraine

Feb. 4, 2019

Eisai plans single phase III confirmatory study of BAN-2401 in early Alzheimer's

Feb. 4, 2019

BREEZE-AD1 and AD2 studies of baricitinib in atopic dermatitis meet primary endpoints

Feb. 4, 2019

FDA clears IND for phase I/IIa trial of VLPM-01 malaria vaccine

Feb. 4, 2019

Circulating miR-3659 found useful for diagnosing dyslipidemia in patients with obesity

Feb. 4, 2019

Tinagl1 protein may be therapeutic in triple-negative breast cancer

Feb. 4, 2019

Moderna exercises option for exclusive licensing agreement with Avacta

Feb. 4, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...